靶向B7-H3的CAR-T细胞免疫疗法在实体瘤中的应用研究进展

The role of B7-H3-targeted chimeric antigen receptor T cell immunotherapy in solid tumors

嵌合抗原受体T(CAR-T)细胞免疫治疗在血液系统恶性肿瘤治疗中取得了显著的成效,为恶性肿瘤治疗带来了曙光,而在实体瘤中的应用面临着巨大的挑战。选择合适的治疗靶点是CAR-T细胞治疗实体瘤的关键。B7-H3蛋白在多种实体瘤中表达量高,与肿瘤的迁移、浸润和发展有关,有望成为实体瘤CAR-T细胞治疗最具潜力的治疗靶点。本文就CAR-T细胞靶点、B7-H3靶点及靶向B7-H3的CAR-T细胞在实体瘤中的研究进展进行总结,为未来CAR-T细胞治疗实体瘤研究提供参考。

The chimeric antigen receptor T(CAR-T)cell immunotherapy has achieved great success in the treatment of hematological malignancies.It brings new hope for the treatment of many malignancies.However,its application in solid tumours still faces enormous challenges.The suitable target antigen was the key to CAR-T cell immunotherapy for solid tumours.B7-H3 protein is highly expressed in a variety of solid tumours,and was related to tumour migration,infiltration and development.It is expected to become the most potential therapeutic target for CAR-T cell therapy in solid tumours.In this article,we summarize the research advance in CAR-T cell targets,B7-H3 target and CAR-T cells targeting B7-H3 in solid tumours,to provide a reference to carry out CAR-T cell solid tumour treatment research.